Zurück

Wählen Sie Ihre Region

Corporate

Europa:

Flagge Albanien Albanien Flagge Bosnien-Herzegowina Bosnien-Herzegowina Flagge Bulgarien Bulgarien Flagge Kroatien Kroatien Flagge Zypern Zypern Flagge Montenegro Montenegro Flagge Tschechien Tschechien Flagge Dänemark Dänemark Flagge Estland Estland Flagge Spanien Spanien Flagge Kosovo Kosovo Flagge Litauen Litauen Flagge Lettland Lettland Flagge Luxemburg Luxemburg Flagge Mazedonien Mazedonien Flagge Deutschland Deutschland Flagge Polen Polen Flagge Portugal Portugal Flagge Rumänien Rumänien Flagge Serbien Serbien Flagge Slowakei Slowakei Flagge Slowenien Slowenien Flagge Schweiz Schweiz Flagge Schweden Schweden Flagge Türkei Türkei Flagge Ungarn Ungarn Flagge Großbritannien Großbritannien Flagge Italien Italien

Asien:

Flagge UAE UAE Flagge Hong Kong Hong Kong Flagge Kuwait Kuwait Flagge Libanon Libanon

Afrika:

Flagge Südafrika Südafrika

Vereinbaren Sie ein Beratungsgespräch über Stammzellen

Mehr erfahren

Kontaktieren Sie uns noch heute!

Möchten Sie mehr über unsere Dienstleistungen erfahren? Füllen Sie das untenstehende Formular aus, und wir werden uns so schnell wie möglich mit Ihnen in Verbindung setzen, um Ihnen alle notwendigen Informationen zu geben und Ihre Fragen zu beantworten.

    Wir möchten Sie darauf hinweisen, dass die im Formular angegebenen personenbezogenen Daten von FamiCord Suisse mit Sitz in der Schweiz (BusinessPark Zug Sumpfstrasse 26, 6302 Zug) zur telefonischen Kontaktaufnahme im Zusammenhang mit der Erteilung von Serviceinformationen verarbeitet werden.

    Obraz

    Unsere
    Transplantationen

    Liste der Verwendungen von Stammzellen, die von den Laboren der FamiCord-Gruppe freigegeben wurden:

    Obraz
    Liste der Verwendungen von Stammzellen, die von den Laboren der FamiCord-Gruppe freigegeben wurden:
    Nr. Quelle Quellentyp Diagnose Medizinbereich Anwendungsjahr Therapie Land Alter des Empfängers
    1701 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 67
    1702 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 67
    1703 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 69
    1704 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 69
    1705 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 70
    1706 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 71
    1707 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 73
    1708 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 60
    1709 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 53
    1710 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 69
    1711 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 59
    1712 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 60
    1713 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 49
    1714 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 52
    1715 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 63
    1716 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 66
    1717 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 58
    1718 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 67
    1719 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 65
    1720 Apheresis Allogeneic Myelodysplastic Syndrome + Myeloma Hematology 2024 Standard Therapy Germany 67
    1721 Apheresis Allogeneic Myelofibrosis Hematology 2024 Standard Therapy Poland 40
    1722 Apheresis Allogeneic Myelofibrosis Hematology 2024 Standard Therapy Poland 58
    1723 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2024 Standard Therapy Poland 60
    1724 Apheresis Allogeneic Myelofibrosis Post. Polycythemia Vera Hematology 2024 Standard Therapy Poland 66
    1725 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2024 Standard Therapy Poland 67
    1726 Apheresis Allogeneic Myeloma Hematology 2024 Standard Therapy Germany 65
    1727 Apheresis Allogeneic Myeloproliferative Neoplasms  Hematology 2024 Standard Therapy Poland 74
    1728 Apheresis Allogeneic Myeloproliferative Neoplasms/Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 68
    1729 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 23
    1730 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 50
    1731 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 50
    1732 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 67
    1733 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 46
    1734 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 65
    1735 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 66
    1736 Apheresis Autologous Non-Hodgkin Lymphoma – relapse Hematology 2024 Standard Therapy Germany 54
    1737 Apheresis Autologous Nonseminoma Hematology 2024 Standard Therapy Germany 38
    1738 Apheresis Allogeneic Osteomyelitis Hematology 2024 Standard Therapy Poland 65
    1739 Apheresis Allogeneic Post-Et-Myelofibrosis Hematology 2024 Standard Therapy Poland 59
    1740 Apheresis Allogeneic Post-Pv-Myelofibrosis Hematology 2024 Standard Therapy Poland 64
    1741 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2024 Standard Therapy Germany 60
    1742 Apheresis Allogeneic Primary Myelofibrosis Hematology 2024 Standard Therapy Poland 52
    1743 Apheresis Allogeneic Primary Myelofibrosis Hematology 2024 Standard Therapy Poland 67
    1744 Apheresis Allogeneic Primary Myelofibrosis Hematology 2024 Standard Therapy Poland 70
    1745 Apheresis Allogeneic Relapsed B-Cell Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 12
    1746 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy Poland 15
    1747 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy Poland 10
    1748 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy Poland 60
    1749 Apheresis Allogeneic Severe Aplastic Anemia Progressed To Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 21
    1750 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 63
    1751 Apheresis Allogeneic Acute myeloid leukemia Hematology 2024 Standard Therapy Germany 64
    1752 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 56
    1753 Apheresis Autologous Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 56
    1754 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 64
    1755 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 56
    1756 Apheresis Autologous Follicular lymphoma Hematology 2024 Standard Therapy Germany 58
    1757 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 65
    1758 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 47
    1759 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 69
    1760 Apheresis Autologous Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 38
    1761 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 65
    1762 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 70
    1763 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 64
    1764 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 53
    1765 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 60
    1766 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 59
    1767 Apheresis Autologous Mantle cell lymphoma Hematology 2024 Standard Therapy Germany 45
    1768 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 66
    1769 Apheresis Autologous Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 33
    1770 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 64
    1771 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 59
    1772 Apheresis Allogeneic Primary myelofibrosis Hematology 2024 Standard Therapy Germany 55
    1773 Apheresis Allogeneic Acute myeloid leukemia Hematology 2024 Standard Therapy Germany 63
    1774 Apheresis Allogeneic Blastic Plasmacytoid Dendritic Hematology 2024 Standard Therapy USA 57
    1775 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 32
    1776 Apheresis Allogeneic Macrofocal multiple myeloma  Hematology 2024 Standard Therapy USA 75
    1777 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy United Kingdom 62
    1778 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 52
    1779 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 48
    1780 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy United Kingdom 71
    1781 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Romania 35
    1782 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Lithuania 47
    1783 Apheresis Allogeneic Diffuse large B-cell lymphoma Hematology 2024 Standard Therapy Australia 46
    1784 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 65
    1785 Apheresis Allogeneic Chronic lymphatic leukemia Hematology 2024 Standard Therapy Norway 52
    1786 Apheresis Allogeneic Chronic myelogenous leukemia Hematology 2024 Standard Therapy Poland 60
    1787 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Hungary 32
    1788 Apheresis Allogeneic Malignant histiocytosis Hematology 2024 Standard Therapy Bulgaria 41
    1789 Apheresis Allogeneic Myelodysplastic syndrome Hematology 2024 Standard Therapy USA 78
    1790 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Hungary 20
    1791 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 58
    1792 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Portugal 67
    1793 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 63
    1794 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Lithuania 19
    1795 Apheresis Allogeneic Hodgkin lymphoma Hematology 2024 Standard Therapy Russia 34
    1796 Apheresis Allogeneic chronic lymphocytic leukemia Richters Transformation Hematology 2024 Standard Therapy United Kingdom 68
    1797 Apheresis Allogeneic Myelodysplasia Hematology 2024 Standard Therapy Sweden 66
    1798 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 52
    1799 Apheresis Allogeneic Myelodysplasia Hematology 2024 Standard Therapy Lithuania 70
    1800 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Germany 72